Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of FLT3-ITD-positive AML treated with gilteritinib
Title: | Myelomonocytic differentiation of leukemic blasts accompanied by differentiation syndrome in a case of FLT3-ITD-positive AML treated with gilteritinib |
Authors: | Kondo, Takeshi Browse this author | Onozawa, Masahiro Browse this author | Fujisawa, Shinichi Browse this author | Harada, Shinpei Browse this author | Ogasawara, Reiki Browse this author | Izumiyama, Koh Browse this author | Saito, Makoto Browse this author | Morioka, Masanobu Browse this author | Mori, Akio Browse this author | Teshima, Takanori Browse this author →KAKEN DB |
Keywords: | Acute myelogenous leukemia | normal karyotype | Fms-like tyrosine kinase 3 | internal tandem duplication | variant allele frequency | differentiation syndrome | FLT3 inhibitor | gilteritinib |
Issue Date: | 1-Jan-2021 |
Publisher: | Taylor & Francis |
Journal Title: | Hematology |
Volume: | 26 |
Issue: | 1 |
Start Page: | 256 |
End Page: | 260 |
Publisher DOI: | 10.1080/16078454.2021.1889111 |
PMID: | 33631087 |
Abstract: | Fms-like tyrosine kinase 3 (FLT3) is one of the most frequently mutated genes in acute myelogenous leukemia (AML) and the mutation is associated with poor prognosis of patients. Two distinct types of activating mutations have been identified in AML samples. One is internal tandem duplications in the juxtamembrane domain (FLT3-ITD) and the other is point mutations in the tyrosine kinase domain (FLT3-TKD). Gilteritinib is a FLT3 inhibitor that inhibits both FLT3-ITD and FLT3-TKD. It was reported that differentiation of leukemic blasts accompanied by differentiation syndrome occurs in some patients treated with gilteritinib. However, information about the precise clinical course is limited, and appropriate management of differentiation syndrome has not been established. We report a case of relapsed AML with FLT3-ITD that was treated with gilteritinib. Analysis of the FLT3-ITD variant allele frequency (VAF) revealed that FLT3-ITD VAF was not decreased despite achievement of complete remission with incomplete hematologic recovery. Remarkable increases of monocytes and granulocytes accompanied by differentiation syndrome were observed at 6 months after the initiation of gilteritinib treatment. Intermittent chemotherapy with low-dose cytarabine and mitoxantrone was effective for reducing myelomonocytosis and resolving differentiation syndrome. |
Type: | article |
URI: | http://hdl.handle.net/2115/81078 |
Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|